Moderate

Bile acid diarrhoea (bile acid malabsorption)

BAD · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Excess colonic bile acids drive secretory, watery diarrhoea, often urgent and post-prandial. Type 1 (ileal disease/resection), type 2 (idiopathic, overlaps IBS-D) and type 3 (post-cholecystectomy, coeliac) are recognised.

Red flags

  • Weight loss, rectal bleeding or anaemia (investigate for IBD/cancer)
  • Features of terminal ileal Crohn's
  • Fat-soluble vitamin deficiency on long-term sequestrant
  • Failure to respond to adequate sequestrant trial

Assessment

Differential diagnosis

  • IBS with diarrhoea
  • Microscopic colitis
  • Crohn's disease (terminal ileum)
  • Pancreatic exocrine insufficiency
  • Coeliac disease
  • Post-cholecystectomy diarrhoea

Investigations

  • SeHCAT retention scan (7-day retention <15% diagnostic; <5% severe)
  • Serum 7α-hydroxy-4-cholesten-3-one (C4) — elevated
  • Fasting serum FGF19 (low)
  • Colonoscopy with biopsies if organic features (exclude microscopic colitis/IBD)
  • Coeliac serology, faecal elastase to exclude mimics

Management

  • Suspect in chronic watery diarrhoea, especially urgency, nocturnal/post-prandial, or post-cholecystectomy/ileal disease
  • Exclude mimics: coeliac serology, calprotectin, faecal elastase
  • Confirm with SeHCAT (or C4/FGF19 where SeHCAT unavailable)
  • Where testing is unavailable, a therapeutic trial of a bile acid sequestrant is reasonable
  • Start a bile acid sequestrant — colestyramine titrated to effect
  • Advise taking sequestrant separately from other medications (≥4 h) to avoid binding
  • Consider colesevelam if colestyramine poorly tolerated (better palatability)
  • Reduce dietary fat to lessen bile acid stimulation
  • Monitor fat-soluble vitamin status with long-term high-dose sequestrants
  • Identify and treat type 1 cause (Crohn's terminal ileitis) specifically
  • Review response and adjust dose; refer to GI if refractory

Drugs & doses

Colestyramine 4 g PO once daily, titrate up to 8–12 g/day in divided doses
Colesevelam 625 mg, 1–3 tablets PO twice daily (better tolerated)
Colestipol 5 g PO once–twice daily (alternative)

Disposition

Outpatient GI management; investigate underlying ileal disease if type 1 suspected.

Complications & pitfalls

  • Dehydration and electrolyte loss
  • Fat-soluble vitamin (A, D, E, K) deficiency
  • Binding and reduced absorption of co-administered drugs
  • Constipation from over-treatment

Exam pearls

  • A large proportion of 'IBS-D' is actually unrecognised bile acid diarrhoea
  • SeHCAT retention <15% at 7 days confirms the diagnosis; lower values predict better sequestrant response
  • Separate sequestrant dosing from levothyroxine, warfarin and other drugs by several hours
  • Colesevelam is better tolerated than colestyramine and improves adherence

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.